Kenneth Hillan

Head of Therapeutics

Kenneth joined 23andMe in 2019 as Head of Therapeutics. He leads a dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases.

At Achaogen, Hillan served as Chief Executive Officer. He held progressively senior roles at Genentech-Roche includin...


Roles at 23andMe

  • Head of Therapeutics

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.